Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
FATE THERAPEUTICS INC shareholders approved Non-binding advisory vote to approve compensation of named executive officers at the 2023-06-06 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-06
Exact text from the filing
Non-binding Advisory Vote on Compensation of Named Executive Officers. For Against Abstain Broker Non-Votes 73,720,442 2,955,503 61,938 10,211,752
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
FATE THERAPEUTICS INC shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm at the 2023-06-06 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-06
Exact text from the filing
Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. For Against Abstain Broker Non-Votes 85,534,350 197,464 1,217,821 —
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
FATE THERAPEUTICS INC shareholders approved Election of three Class I Directors at the 2023-06-06 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-06
Exact text from the filing
Election of Class I Directors. Director Nominee For Withheld Broker Non-Votes Robert S. Epstein, M.D., M.S. 74,088,457 2,649,426 10,211,752 John D. Mendlein, Ph.D., J.D. 65,801,671 10,936,212 10,211,752 Karin Jooss, Ph.D. 74,481,093 2,256,790 10,211,752
View on SEC.gov